drugset / Trial / NCT06422689

Combination Short-Acting BroNchodilator and Inhaled Corticosteroid Rescue Therapy on Health Outcomes in Routine Care

NCT06422689

Phase 4 Active not recruiting 1511 enrolled AstraZeneca Premier HealthCare Solutions Inc. · collab
NaSingle-groupOpen-labelTreatment

Summary

ANCHOR is a prospective, phase IV, interventional, single-arm, open-label study of 1,500 adult participants with symptomatic asthma requiring the use of rescue therapy aimed to compare the asthma exacerbation rates before and after switching from albuterol or levalbuterol to albuterol plus budesonide inhalation aerosol as rescue therapy.

Timeline

Start
2024-05-10
Primary completion
2027-02-03
Completion
2027-02-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Budesonide Small molecule 160 ug Inhaled
Subject Salbutamol Unknown 180 ug Inhaled

Indications